Orchid Pharma's Exblifep Granted European Medicines Agency Approval: A Landmark Achievement for India's Pharmaceutical Industry

Orchid Pharma, a Dhanuka Group Company, has achieved a significant breakthrough with its antibiotic invention, 'Exblifeb', which has received the European Medicines Agency's (EMA) recommendation for marketing authorization. This is the first instance of an Indian-invented drug reaching this stage of clinical development, marking a landmark achievement for India's pharmaceutical industry. Exblifeb, which incorporates Enmetazobactam, a completely invented-in-India Beta Lactamase Inhibitor, demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia, and bacteremia caused by Extended Spectrum Beta-lactamase producing pathogens. This milestone positions Exblifeb as a front-runner in combating Anti-Microbial Resistance (AMR) and underscores the urgent need for effective solutions to address the global health crisis.,